China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Trump Buys SpaceX Shares After Record IPO 
Nvidia Options Price in $280 Billion Earnings Swing 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 01, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8, 2018.
Management will host a conference call on that date at 8:00 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 7665388. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
